The Drug Evaluation Branch of the Developmental Therapeutics Program, Division of Cancer Treatment (DCT), National Cancer Institute (NCI) is seeking a contractor with the expertise to evaluate compounds for anticancer activity in experimental tumor models, including both murine tumors growing in conventional mice and human tumors growing in athymic mice. Emphasis will be placed on testing congeners and pro-drugs of newly identified lead compounds (synthetic and natural product) under well-controlled experimental conditions in order to guide synthetic efforts and identify the most promising member of a class for further development. Also a limited number of secondary evaluations will be performed to address specific questions related to anticancer activity which arise during the course of developing agents to clinical trial.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM067724-000
Application #
3614188
Study Section
Project Start
1986-02-16
Project End
1989-02-15
Budget Start
1986-02-16
Budget End
1987-02-15
Support Year
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Southern Research Institute
Department
Type
DUNS #
006900526
City
Birmingham
State
AL
Country
United States
Zip Code
35205
Grem, J L; Plowman, J; Rubinstein, L et al. (1991) Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model. Leuk Res 15:229-36